drugset / Trial / NCT03773562
Imaging the Migraine Brain Pre- and Post-Erenumab
NaSingle-groupOpen-labelTreatment
Summary
Researchers are trying to determine if there is a difference between brain images of subjects that do respond to treatment with erenumab and subjects who do not respond to treatment with erenumab using Magnetic Resonance Imaging (MRI).
Timeline
- Start
- 2019-03-25
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erenumab | Monoclonal antibody | 140 mg | Subcutaneous |